A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers

Molecular Membrane Biology

Volumn 27, Issue 7, 2010, Pages 260-273

  Ganta, Srinivas ^a   Deshpande, Dipti ^a   Korde, Anisha ^a   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

blood brain barrier; cytochrome P450; multifunctional nanoemulsions; nanotechnology; Oral; P glycoprotein

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALKALINE PHOSPHATASE; AMINE OXIDASE (FLAVIN CONTAINING); AROMATIC CARBOXYLIC ACID; CATECHOL METHYLTRANSFERASE; DIPEPTIDYL PEPTIDASE IV; EDIBLE OIL; EPOXIDE HYDROLASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; GAMMA GLUTAMYLTRANSFERASE; GLUTAMYL AMINOPEPTIDASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 2; OCTAMER TRANSCRIPTION FACTOR 4; PENTETIC ACID; POLYUNSATURATED FATTY ACID; SURFACTANT;

ACETYLATION; ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CAPILLARY ENDOTHELIUM; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; FIRST PASS EFFECT; GASTROINTESTINAL TRACT; GLUCURONIDATION; HYDROLYSIS; INTESTINE CELL; INTESTINE EPITHELIUM; METHYLATION; NANOEMULSION; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; OXIDATION; PRIORITY JOURNAL; REDUCTION; REVIEW; STOMACH EMPTYING; SULFATION; TIGHT JUNCTION; TRANSCYTOSIS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CELL MEMBRANE PERMEABILITY; CENTRAL NERVOUS SYSTEM AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EMULSIONS; GASTROINTESTINAL TRACT; HUMANS; NANOTECHNOLOGY; P-GLYCOPROTEIN; TIGHT JUNCTIONS;

EID: 78049346336     PISSN: 09687688     EISSN: 14645203     Source Type: Journal    
DOI: 10.3109/09687688.2010.497971     Document Type: Review

References (98)

1. Abbott NJ. 2002. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 200:629-638.
2. Abbott NJ. 2005. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol 25:5-23.
3. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. 2010. Structure and function of the blood-brain barrier. Neurobiol Dis 37:13-25.
4. Amidon GL, LennernasH,Shah VP, Crison JR. 1995.Atheoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
5. Aungst BJ. 1999. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev 39:105-116.
6. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. 2004. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 447:735-743.
7. Bali V, Ali M, Ali J. 2010. Novel nanoemulsion for minimizing variations in bioavailability of ezetimibe. J Drug Target Article online in advance of print-DOI 10.3109/10611860903548362.
8. Barchet TM, Amiji MM. 2009. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv 6:211-225.
9. Beduneau A, Saulnier P, Benoit JP. 2007. Active targeting of brain tumors using nanocarriers. Biomaterials 28:4947-4967.
10. Begley DJ, Brightman MW. 2003. Structural and functional aspects of the blood-brain barrier. Prog Drug Res 61:39-78.
11. Benet LZ, Cummins CL, Wu CY. 2004. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3-9.
12. Brasnjevica I, Steinbuscha H, Schmitza C, Martinez-Martinez P. 2009. Delivery of peptide and protein drugs over the blood brain barrier. Prog Neurobiol 87:212-251.
13. Buggins T, Dickinson P, Taylor G. 2007. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev 59:1482-1503.
14. Cho K, Wang X, Nie S, Chen ZG, Shin DM. 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14:1310-1316.
15. Cornford EM. 1985. The blood brain barrier, a dynamic regulatory interface. Mol Physiol 7:219-259.
16. Danielson PB. 2002. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 3:561-597.
17. Dean M, Annilo T. 2005. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Geno-mics Hum Genet 6:123-142.
18. Deeley RG, Westlake C, Cole SP. 2006. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86:849-899.
19. Deli MA. 2009. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 1788:892-910.
20. Demeule M, Regina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, Moghrabi A, Beliveau R. 2002. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 38:339-348.
21. Edmond J. 2001. Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J Mol Neurosci 16:181-193; discussion 215-221.
22. Eraly SA, Bush KT, Sampogna RV, Bhatnagar V, Nigam SK. 2004. The molecular pharmacology of organic anion transporters: from DNA to FDA? Mol Pharmacol 65:479-487.
23. Eyal S, Hsiao P, Unadkat JD. 2009. Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123: 80-104.
24. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G. 2002. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110:1309-1318.
25. Ferrari M. 2005. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5:161-171.
26. Florence AT. 2005. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today 2:75-81.
27. Fricker G, Miller DS. 2004. Modulation of drug transporters at the blood-brain barrier. Pharmacology 70:169-176.
28. Ganta S, Amiji M. 2009. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6:928-939.
29. Ganta S, Devalapally H, Amiji M. 2010. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of pac-litaxel upon administration in nanoemulsion formulation. J Pharm Sci Article online in advance of print-DOI: 10.1002/jps.22157.
30. Ganta S, Devalapally H, Baguley B, Garg S, Amiji M. 2008a. Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-apoptotic activity in tumor cells. J Biomed Nanotechnol 4:165-173.
31. Ganta S, Paxton JW, Baguley BC, Garg S. 2008b. Pharmacoki-netics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. Int J Pharm 360:115-121.
32. Ganta S, Sharma P, Garg S. 2008c. Permeability assessment. New York: Wiley-Interscience.
33. Ganta S, Sharma P, Paxton JW, Baguley BC, Garg S. 2010. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion. J Drug Target 18(2): 125-133.
34. Gindy ME, Prud'homme RK. 2009. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv 6:865-878.
35. Goldberg M, Gomez-Orellana I. 2003. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2:289-295.
36. Golden PL, Pollack GM. 2003. Blood-brain barrier efflux transport. J Pharm Sci 92:1739-1753.
37. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
38. Gray JH, Owen RP, Giacomini KM. 2004. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 447:728-734.
39. Greish K. 2007. Enhanced permeability and retention of macro-molecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 15:457-464.
40. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. 1999. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 16:1564-1569.
41. Hagenbuch B, Meier PJ. 2004. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447: 653-665.
42. Hawkins BT, Egleton RD. 2008. Pathophysiology of the blood-brain barrier: animal models and methods. Curr Top Dev Biol 80:277-309.
43. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, Bruford EA. 2004. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch 447:465-468.
44. Hochman J, Artursson P. 1994. Mechanism of absorption enhancement and tight junction regulation. J Control Release 29: 253-267.
45. Hubensack M, Muller C, Hocherl P, Fellner S, Spruss T, Bernhardt G, Buschauer A. 2008. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134: 597-607.
46. Jabr-Milane LS, Van Vlerken LE, Yadav S, Amiji MM. 2008. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 34:592-602.
47. Jeffrey P, Summerfield S. 2010. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol Dis 37:33-37.
48. Jones PM, George AM. 2004. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 61:682-699.
49. Kim KY. 2007. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine 3:103-110.
50. Koning GA, Krijger GC. 2007. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem 7:425-440.
51. Kusuhara H, Sugiyama Y. 2005. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2:73-85.
52. La Guardia M, Giammanco S, Di Majo D, Tabacchi G, Tripoli E, Giammanco M. 2005. Omega 3 fatty acids: biological activity and effects on human health. Panminerva Med 47:245-257.
53. Lennernas H, Abrahamsson B. 2005. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol 57:273-285.
54. Levchenko TS, Rammohan R, Lukyanov AN, Whiteman KR, Torchilin VP. 2002. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 240:95-102.
55. Loscher W, Potschka H. 2005a. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2: 86-98.
56. Loscher W, Potschka H. 2005b. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76. (Pubitemid 41033402)
57. Luurtsema G, De Lange EC, Lammertsma AA, Franssen EJ. 2004. Transport across the blood-brain barrier: stereoselectivity and PET-tracers. Mol Imaging Biol 6:306-318.
58. Madhusudhan B, Rambhau D, Apte SS, Gopinath D. 2007. 1-O-alkylglycerol stabilized carbamazepine intravenous o/w nanoemulsions for drug targeting in mice. J Drug Target 15:154-161. (Pubitemid 46957702)
59. Malingre MM, Beijnen JH, Schellens JH. 2001. Oral delivery of taxanes. Invest New Drugs 19:155-162.
60. Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, Casado FJ, Clotet B, Pastor-Anglada M, Martinez-Picado J. 2008. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther 324: 558-567.
61. Mossink MH, Van Zon A, Scheper RJ, Sonneveld P, Wiemer EA. 2003. Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 22:7458-7467.
62. Nies AT. 2007. The role of membrane transporters in drug delivery to brain tumors. Cancer Lett 254:11-29.
63. Nishioka Y, Yoshino H. 2001. Lymphatic targeting with nanopar-ticulate system. Adv Drug Deliv Rev 47:55-64.
64. Oyewumi MO, Liu S, Moscow JA, Mumper RJ. 2003. Specific association of thiamine-coated gadolinium nanoparticles with human breast cancer cells expressing thiamine transporters. Bioconjug Chem 14:404-11.
65. Pardridge WM. 1999. Blood-brain barrier biology and methodology. J Neurovirol 5:556-569.
66. Pardridge WM. 2002. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131-139.
67. Pardridge WM. 2007. Blood-brain barrier delivery. Drug Discov Today 12:54-61.
68. Patlolla RR, Vobalaboina V. 2008. Folate-targeted etoposide-encapsulated lipid nanospheres. J Drug Target 16:269-275.
69. Pierre K, Pellerin L. 2005. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J Neurochem 94:1-14.
70. Potschka H. 2010. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol Ther 125:118-127.
71. Rajagopal A, Simon SM. 2003. Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell 14: 3389-3399.
72. Redzic ZB, Biringer J, Barnes K, Baldwin SA, Al-Sarraf H, Nicola PA, Young JD, Cass CE, Barrand MA, Hladky SB. 2005. Polarized distribution of nucleoside transporters in rat brain endothelial and choroid plexus epithelial cells. J Neurochem 94:1420-1426.
73. Salama N, Eddington N, Fasano A. 2006. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 58:15-28.
74. Sarker DK. 2005. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv 2:297-310.
75. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ. 2000. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12:550-556.
76. Seelig A. 1998. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252-261.
77. Seelig A, Landwojtowicz E. 2000. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 12:31-40.
78. Shimazawa M, Nakajima Y, Mashima Y, Hara H. 2009. Docosa-hexaenoic acid (DHA) has neuroprotective effects against oxi-dative stress in retinal ganglion cells. Brain Res 1251:269-275.
79. Soontornmalai A, Vlaming ML, Fritschy JM. 2006. Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 138:159-169.
80. Stevenson BR. 1998. The tight junction: morphology to molecules. Annu Rev Cell Dev Biol 14:89-109.
81. Straubinger RM, Arnold RD, Zhou R, Mazurchuk R, Slack JE. 2004. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res 24:397-404.
82. Taogoshi T, Nomura A, Murakami T, Nagai J, Takano M. 2005. Transport of prostaglandin E1 across the blood-brain barrier in rats. J Pharm Pharmacol 57:61-66.
83. Thummel K, Kunze K, Shen D. 1997. Enzyme catalyzed processes of first pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99-127.
84. Tiwari S. 2007. Nanoemulsion formulations for tumor-targeted delivery. In: Mansoor M. Amiji, editor. Nanotechnology for cancer therapy. New York: CRC Press.
85. Tiwari S, Amiji M. 2006a. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol 9:3215-3221. (Pubitemid 44580003)
86. Tiwari S, Tan Y-M, Amiji M. 2006. Preparation and in vitro characterization of multifunctional nanoemulsions for simultaneous MR imaging and targeted drug delivery. J Biomed Nano-technol 2:217-224.
87. Tiwari SB, Amiji MM. 2006b. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 3:219-232.
88. Torchilin VP. 2002. PEG-based micellesas carriersofcontrast agents for different imagingmodalities. Adv DrugDelivRev54:235-252.
89. Torchilin VP. 2006. Multifunctional nanocarriers. Adv Drug Deliv Rev 58:1532-1555.
90. Van Asperen J, Van Tellingen O, Van Der Valk MA, Rozenhart M, Beijnen JH. 1998. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 4:2293-2297.
91. Varatharajana L, Thomas S. 2009. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recomendations for further research. Antiviral Res 82: A99-A109.
92. Vyas TK, Shahiwala A, Amiji MM. 2008. Improved oral bio-availability and brain transport of saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm 347:93-101.
93. Wickline SA, Lanza GM. 2003. Nanotechnology for molecular imaging and targeted therapy. Circulation 107:1092-1095.
94. Wolburg H, Lippoldt A. 2002. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38:323-337.
95. Wolburg H, Wolburg-Buchholz K, Liebner S, Engelhardt B. 2001. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. Neurosci Lett 307:77-80.
96. Yang SC, Benita S. 2000. Enhanced absorption and drug targeting by positively charged submicron emulsions. Drug Develop Res 50:476-486.
97. Zhang W, Tan TM, Lim LY. 2007. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the phar-macokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 35:110-115.
98. Zhang Y, Benet LZ. 2001. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168.